

10/509, 292

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	(Drivas near Dimitrios).in.	US-PGPUB; USPAT	OR	ON	2007/05/16 13:45
L2	10	Drivas.in.	US-PGPUB; USPAT	OR	ON	2007/05/16 13:48
L3	23	Drivas.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 13:50
L4	1929	eotaxin\$ or scyall or ccl11	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 13:50
L5	32	L4 same vaccin\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 13:56
L6	431	L4 same (allerg\$ or asthma\$)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:01
L7	1	Wo-200207011-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:02
L8	0	Wo-2002070711-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 17:16
L9	0	WO-2002070711-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:03
L10	2	WO-9929728-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:44
L11	1	WO-200180887-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:48

## EAST Search History

L12	0	WO-2002056905-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 15:03
L13	4	2002WO-IB00166.ap.prai.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:53
L14	2	"20030157479".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 14:53
L15	2	WO-2004096849-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 16:30
L16	1	"6093405".pn.	US-PGPUB; USPAT	OR	ON	2007/05/16 16:59
L17	1654	chemokin\$ same vaccin\$	US-PGPUB; USPAT	OR	ON	2007/05/16 16:59
L18	27	L17 same asthma	US-PGPUB; USPAT	OR	ON	2007/05/16 17:02
L19	24	L17 same (eotaxin or ccl11)	US-PGPUB; USPAT	OR	ON	2007/05/16 17:02
L20	1	Wo-200004926-\$ did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 17:16

10/509,292

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 14:10:20 ON 16 MAY 2007

L1 1 S DRIVAS D/AU

L2 0 S DRIVAS/AU

L3 7 S DRIVAS D?/AU

L4 4 DUP REM L3 (3 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:11:51 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:13:09 ON 16 MAY 2007

E "EOTAXIN"/CN 25

L5 1 S E11

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, USPATFULL, PCTFULL' ENTERED AT  
14:15:10 ON 16 MAY 2007

L6 9453 S L5 OR EOTAXIN OR CCL11

L7 9453 S E11 OR EOTAXIN OR CCL11

L8 9573 S 181315-51-5 OR EOTAXIN? OR CCL11

L9 90 S L8 (S) VACCIN?

L10 69 DUP REM L9 (21 DUPLICATES REMOVED)

L11 69 SORT L10 PY A

FILE 'STNGUIDE' ENTERED AT 14:22:02 ON 16 MAY 2007

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 15:11:27 ON 16 MAY 2007

L12 664 S (EOTAXIN OR CCL11 OR SCYA11) (S) ASTHMA

L13 0 S L2 (S) (IMMUNIZAT? OR VACCIN?)

L14 7 S L12 (S) (IMMUNIZAT? OR VACCIN?)

L15 4 DUP REM L14 (3 DUPLICATES REMOVED)

=>

10/509,292 SEQ ID NO:16

<!--StartFragment--> Amino acid sequence of chemokine receptor ligand eotaxin.  
XX  
KW Chemokine receptor; ligand; inflammatory response; immune effector cell;  
KW secondary tissue damage; central nervous system injury; eotaxin;  
KW CNS inflammatory disease; neurodegenerative disorder; heart disease;  
KW inflammatory eye disease; inflammatory bowel disease;  
KW inflammatory joint disease; inflammatory kidney; renal disease;  
KW inflammatory lung disease; inflammatory nasal disease;  
KW inflammatory thyroid disease; thyroiditis; cytokine-regulated cancer.  
XX  
OS Homo sapiens.  
XX  
PN WO200004926-A2.  
XX  
PD 03-FEB-2000.  
XX  
PF 21-JUL-1999; 99WO-CA000659.  
XX  
PR 22-JUL-1998; 98US-00120523.  
XX  
PA (OSPR-) OSPREY PHARM LTD.  
XX  
PI McDonald JR, Coggins PJ;  
XX  
DR WPI; 2000-182542/16.  
XX  
PT A new therapeutic agent comprising a conjugate for treating secondary  
PT tissue damage and other disease conditions like Alzheimer's disease,  
PT stroke, Parkinson's disease and atherosclerosis.  
XX  
PS Disclosure; Page 59; 204pp; English.  
XX  
CC The present sequence represents a chemokine receptor ligand. The present  
CC ligand can be incorporated into the conjugates of the invention. The  
CC specification describes a conjugate, comprising a targeted agent and a  
CC chemokine receptor ligand. The conjugate binds to a chemokine receptor  
CC resulting in internalisation of the targeted agent in cells bearing the  
CC receptor. The conjugates are used for formulating a medicament or for  
CC treating disorders associated with inflammatory responses resulting from  
CC activation, proliferation and migration of immune effector cells. The  
CC disorders or disease states comprise secondary tissue damage such as  
CC central nervous system (CNS) injury, CNS inflammatory diseases,  
CC neurodegenerative disorders, heart disease, inflammatory eye diseases,  
CC inflammatory bowel diseases, inflammatory joint diseases, inflammatory  
CC kidney or renal diseases, inflammatory lung diseases, inflammatory nasal  
CC diseases, inflammatory thyroid disease such as thyroiditis, or cytokine-  
CC regulated cancers  
XX  
SQ Sequence 74 AA;

Query Match 100.0%; Score 20; DB 3; Length 74;  
Best Local Similarity 100.0%; Pred. No. 5.2e-13;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GPASVPTTCCFNLANRKIPL 20  
||| ||| ||| ||| ||| ||| |||  
Db 1 GPASVPTTCCFNLANRKIPL 20

<!--EndFragment-->